Incyte (INCY) Reiterated at Buy by Truist, Dip is a Buying Opportunity, Opzelura Launch is Key Highlight
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
